The problem of evaluation of comprehensive care

 

From Prof. Dr. Ettore Beghi, Milan, Italy

 

Berlin (20. September 2008) – Comprehensive care in epilepsy, as with any chronic clinical condition, refers to the management of the disease and its complications and comorbidities aiming to obtain the maximal benefits in terms of satisfactory control of the symptoms in keeping with patients’ satisfaction and quality of life. Little is known about the impact of comprehensive care of epilepsy and this reflects into different patterns of care both at the primary level and in epilepsy clinics and other secondary and tertiary centres. There are several explanations for this: 1. The different characteristics and outcome of acute symptomatic seizures, isolated unprovoked seizures and epilepsy, which are frequently defined interchangeably; 2. The ill-defined association between epilepsy and several other clinical conditions, like depression (and other psychiatric disorders), headache and sleep disturbances; 3. The increasing number of drugs having different safety and tolerability profiles and effects on some comorbid conditions; 4. The differing perspectives of patients, caring physicians, and health care administrators regarding the cost-benefit ratio of the management of epilepsy; 5. An as yet lacking formal, evidence-based assessment of comprehensive care in epilepsy.

 

Acute symptomatic seizures (ie, seizures caused by immediate CNS insults), isolated unprovoked seizures and epilepsy (ie, repeated unprovoked seizures) represent clinical conditions having different severity and outcome and may require differing diagnostic and therapeutic management and a differing  approach at the primary (ie, general practitioner), secondary (ie, neurologist), and tertiary (ie, epileptologist) level. As well, the medical interventions may differ at the time of occurrence of a seizure and in the follow-up, when a full diagnostic and therapeutic work-up is required. Comorbidities require proper attention because a bidirectional cause-effect relationship may be present (Slides 1 & 2) and because ad-hoc treatments may be indicated. Epilepsy complications may be identified and managed to the benefit of the patient, in terms of satisfaction and quality of life, and to reduce disease-related direct and indirect costs. Second-generation antiepileptic drugs (AEDs) are currently available in increasing numbers. Although these compounds do not compete with classic AEDs in terms of efficacy, their pharmacokinetic and tolerability profiles are different and, in some occasions, better than those of the competitors. In addition, some of them have been found effective against symptoms of other comorbid disorders, like depression, headache and pain (Slide 3). Doctors’ main objective in the overall management of epilepsy is seizure control. In contrast, for the patient the focus of the disease management would be the use of drugs with minimal or no impact on daily living activities and overall quality of life. In this regard, the tolerability of a treatment may be more important than its efficacy. The health-care administrator looks for a cost-effective management with scarce impact on the available resources, in terms of minimal access to health care facilities and low monetary costs.

 

Surprisingly, the poverty of good quality reports does not provide sufficient high-level evidence in support of evidence-based standards of care in patients with epilepsy in a number of differing contexts: 1. The role of primary care and its interface with secondary care; 2. The role of physicians involved in the acute management of the disease and those required to complete the diagnostic and therapeutic work-up; 3. The cost-benefit ratio of epilepsy clinics and other tertiary centres compared to the other facilities dedicated to the care of epilepsy; 4. The impact of educational tools on improving the care of epilepsy by the different actors; 5. The integration of the patients’ views into the decision process.

 

In the light of the available evidence on the effectiveness of epilepsy services, more studies with robust methodology are required to support the best evidence-based recommendations and identify the most effective models of service provision for patients with epilepsy.

 

 

Beghi_1

 

Slide 1: Depression as a risk factor of epilepsy.

 

 

Beghi_2

 

Slide 2: Comorbidity of migraine and epilepsy.

 

 

Beghi_3

 

Slide 3: Effects of antiepileptic drugs on depression/mood, migraine and neuropathic pain.

 

 

 


 

Source: 8th European Congress on Epiteptology, Satellite Symposium: “Comprehensive Care of Epilepsy in Europe”, Berlin, 20. September 2008 (Medizin und PR Kommunikation).

MEDICAL NEWS

Fitness watches generate useful information, but increase patient anxiety
A new device provides added protection against COVID-19 during endoscopic…
81 million Americans lacking space or bathrooms to follow COVID…
Front-line physicians stressed and anxious at work and home
EULAR: High-Dose Glucocorticoids and IL-6 Receptor inhibition can reduce COVID-19…

SCHMERZ PAINCARE

Morbus Fabry mittels Datenanalysen aus dem PraxisRegister Schmerz aufspüren
Neandertaler besaßen niedrigere Schmerzschwelle
Deutscher Schmerz- und Palliativtag 2020 – ONLINE
Deutsche Gesellschaft für Schmerzmedizin fordert Anerkennung von Nicht-Psychologen in der…
DBfK: Besondere Rolle für Pflegeexpert/innen Schmerz – nicht nur in…

DIABETES

“Körperstolz”: Michael Krauser managt seinen Diabetes digital
Der richtige Sensor – von Anfang an
Diabetes mellitus: Ein Risikofaktor für frühe Darmkrebserkrankungen
Fastenmonat Ramadan: Alte und neue Herausforderung für chronisch Erkrankte während…
Sanofi setzt sich für die Bedürfnisse von Menschen mit Diabetes…

ERNÄHRUNG

Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren
Gesundheitliche Auswirkungen des Salzkonsums bleiben unklar: Weder der Nutzen noch…
Fast Food, Bio-Lebensmittel, Energydrinks: neue Daten zum Ernährungsverhalten in Deutschland
Neue Daten zur Ernährungssituation in deutschen Krankenhäusern und Pflegeheimen: Mangelernährung…
Baxter: Parenterale Ernährung von Patienten mit hohem Aminosäurenbedarf

ONKOLOGIE

Darolutamid bei Prostatakarzinom: Hinweis auf beträchtlichen Zusatznutzen
Multiples Myelom: Wissenschaftler überprüfen den Stellenwert der Blutstammzelltransplantation
Neues zur onkologischen Supportiv- und Misteltherapie und aktuelle Kongress-Highlights zum…
Finanzierung der ambulanten Krebsberatung weiterhin nicht gesichert
Lungenkrebsscreening mittels Low-Dose-CT

MULTIPLE SKLEROSE

Geschützt: Multiple Sklerose: Novartis’ Siponimod verzögert Krankheitsprogression und Hirnatrophie bei…
Neurofilamente als Diagnose- und Prognosemarker für Multiple Sklerose
Bedeutung der Langzeittherapie bei Multipler Sklerose – mehr Sicherheit und…
Bristol Myers Squibb erhält Zulassung der Europäischen Kommission für Ozanimod…
Einige MS-Medikamente könnten vor SARS-CoV-2/COVID-19 schützen

PARKINSON

Neue Studie zur tiefen Hirnstimulation bei Parkinson-Erkrankung als Meilenstein der…
Putzfimmel im Gehirn
Parkinson-Patienten in der Coronakrise: Versorgungssituation und ein neuer Ratgeber
Neuer Test: Frühzeitige Differenzialdiagose der Parkinson-Erkrankung
Gegen das Zittern: Parkinson- und essentiellen Tremor mit Ultraschall behandeln…